Showing results (1-10 of 337) with videos related to
Sort By:
Pageof 34
Expert Review of Clinical Immunology|November 26, 2019
Remission maintenance in ANCA-associated vasculitis: does one size fit all?Alvise Berti, Ulrich SpecksBest Practice & Research. Clinical Rheumatology|December 12, 2018
Update on the epidemiology, risk factors, and outcomes of systemic vasculitidesAlvise Berti, Christian DejacoExpert Opinion on Pharmacotherapy|May 19, 2023
Advances in the pharmacotherapeutic management of eosinophilic granulomatosis with polyangiitisChristian Pagnoux, Alvise BertiSeminars in Arthritis and Rheumatism|February 27, 2025
Sodium-glucose cotransporter 2 (SGLT2) inhibition and autoimmunityAndreas KronbichlerMayo Clinic Proceedings|April 5, 2021
Obesity is a Major Risk Factor for Hospitalization in Community-Managed COVID-19 PneumoniaMarcello Cottini, Carlo Lombardi, Alvise Berti, et al.Drugs in Context|July 29, 2024
Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case seriesCarlo Lombardi, Francesco Menzella, Alvise BertiCurrent Research in Immunology|May 2, 2022
The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditionsCarlo Lombardi, Alvise Berti, Marcello CottiniRheumatic Diseases Clinics of North America|June 18, 2023
Treatment Approaches to Granulomatosis with Polyangiitis and Microscopic PolyangiitisAlvise Berti, Divi Cornec, Anisha B DuaNephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 6, 2018
Pro: Contrast-induced nephropathy-should we try to avoid contrast media in patients with chronic kidney disease?Martin Windpessl, Andreas KronbichlerAnnals of the Rheumatic Diseases|November 30, 2021
Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitorsMarcus Säemann, Andreas KronbichlerPageof 34